BAX Stock Analysis — Baxter International
Sector: Healthcare
AI Verdict
Baxter looks cheap for a defensive healthcare name at 13.6x forward earnings, but the overbought RSI means the next move is likely down before any value gets unlocked.
Competitive Moat
Baxter International manufactures critical hospital products like IV solutions, infusion pumps, and renal therapies, which are deeply embedded in hospital supply chains. Its moat comes from regulatory approvals and long-term hospital contracts that create high switching costs and stable recurring demand.
Summary
Baxter trades at just 13.6x forward earnings while its RSI of 76.0 signals the stock is technically overbought.
Where It Stands
Baxter's 16.29% one-year return and 13.6x forward P/E are both ahead of the sector's 22x median, but an RSI of 76.0 suggests a near-term pullback risk.
Key Metrics
- RSI: 76 — Overbought
- Forward P/E: 13.6x
- Revenue Growth: +0.1%
- Market Cap: $14.2B
- Dividend Yield: 0.00%
- 1-Year Return: 16.29%
- 52-Week High: $30.00
- 52-Week Low: $15.73
Analyst Consensus
5 Buy · 14 Hold · 1 Sell (20 analysts)
Bull Case
The 13.6x forward P/E is cheap compared to the healthcare sector's 22x median, especially with 5.4% revenue growth and entrenched hospital relationships.
Bear Case
With an RSI of 76.0, a technical correction could easily knock 10–15% off the current price even if fundamentals remain intact.
Catalyst to Watch
Watch for upcoming earnings — any acceleration in revenue growth above the current 5.4% could justify a higher multiple.